Connecting therapeutic robots can reduce patient stress: Early trials of Hana-chan reveal the potential of emotional AI in medical applications

Therapeutic Robots Enter Clinical Validation Stage

At the recent HIMSS26 Europe conference, Peter Julius, CEO and Partner of Public Intelligence, presented early trial results for the social robot Hana-chan. The data shows that this therapeutic robot can significantly reduce patient stress and help aggressive patients relax. Julius noted that Hana-chan was designed to assist caregivers by improving patients' emotional well-being through affective interaction.

Industry Background: The Intersection of Emotional AI and Medical Robotics

With the rapid advancement of Digital Health and AI Healthcare, robots are no longer limited to surgical or logistics tasks but are beginning to take on psychological support roles. Hana-chan belongs to the "socially assistive robot" category, combining facial recognition, voice interaction, and affective computing technologies to simulate empathetic responses. Such devices fall under wearable or interactive devices within Medical Devices and also belong to the human-machine interaction research area of Biotech Innovation.

The global shortage of caregivers is becoming increasingly severe, especially in elderly care and long-term care facilities in Europe and Asia. Therapeutic robots offer a low-cost auxiliary solution that can alleviate the burden on caregivers while improving patient experience.

Key Progress: Early Trials of Hana-chan

According to Julius, the early trials of Hana-chan were conducted in multiple care settings. After establishing a connection with the robot, patients showed positive changes such as reduced stress levels and improved emotional stability. The calming effect of the robot was particularly significant for patients with aggressive behavior. Although these results are preliminary, they have attracted widespread attention in the medical technology field.

Notably, the robots in the trial were not simply pre-programmed responders but possessed certain AI learning capabilities, allowing them to adjust interaction patterns based on patient responses. This kind of personalized emotional support is a core direction for the future development of Healthcare Technology.

Market Impact: Which Companies May Benefit?

The therapeutic robot market is on the verge of a boom. In addition to Public Intelligence, Japanese companies such as SoftBank Robotics (with Pepper) and UBTECH are also exploring emotional robots. Moreover, technology companies focused on elderly care and mental health will directly benefit.

In the HealthTech investment space, venture capital is increasingly turning to affective computing and social robots. According to market research, the global social robot market is expected to reach tens of billions of dollars by 2030, with medical applications accounting for a significant share.Hospitals and nursing institutions have also begun piloting such devices. For example, some nursing homes in Europe have introduced the predecessor of Hana-chan to observe long-term effects. If subsequent trials confirm cost-effectiveness, large-scale procurement could drive Healthcare Innovation into a new phase.

Challenges and Risks

Despite the promising outlook, therapeutic robots still face multiple challenges. The first is regulatory issues: as Medical AI devices, their clinical effectiveness and safety require strict approval. The European Medical Device Regulation (MDR) has a complex certification process for such products.

The second is data privacy: the patient emotion and behavior data collected by robots are sensitive information, and ensuring compliance with medical data regulations is a core issue.

Finally, ethical controversies: machines replacing human emotional support may raise questions about the quality of care. The industry needs to establish a clear ethical framework.

Future Outlook (3–5 years)

It is expected that within the next three years, therapeutic robots will move from early trials to larger-scale empirical studies. Advances in AI Healthcare will make robots more personalized, for example, by integrating electronic medical record data to provide customized emotional support. Meanwhile, telemedicine platforms may integrate therapeutic robots as part of remote mental health services.

Driven by capital, several startups have already begun to position themselves in the emotional AI medical track. If clinical evidence for products like Hana-chan is further consolidated, the field is likely to see a wave of mergers and acquisitions.

Conclusion

The early trials of Hana-chan not only validate the potential of therapeutic robots in reducing patient stress but also mark the official entry of emotional AI into the medical industry's field of vision. With the aging population and growing demand for mental health, the technical route combining robots and affective computing will become an important direction for Healthcare Innovation. Market participants should closely monitor regulatory developments and clinical trial progress in order to take the initiative in the upcoming digital care transformation.